Eur Rev Med Pharmacol Sci 2020; 24 (12): 6597-6604

DOI: 10.26355/eurrev_202006_21645

Elevated CISD2 expression predicts poor diagnosis and promotes invasion and migration of prostate cancer cells

Q.-Q. Zhu, L. Tian, D.-L. Li, Z.-H. Wu, Y.-Y. He, H.-K. Zhang

Department of Vascular Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. 1198050@zju.edu.cn


OBJECTIVE: To explore roles of CDGSH iron-sulfur domain-containing protein 2 (CISD2) in the progression of prostate cancer (PCa) cells, and relationships between CISD2 expression and the prognosis and clinical pathological parameters in PCa patients.

PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) analysis and Western blot analysis were used to detect the CISD2 expression in PCa tissues and cells. CISD2 siRNA was used to inhibit the CISD2 expression. Kaplan-Meier method and Log rank analysis were performed to determine survival analysis while Chi-square test was performed to analyze the association between CISD2 and clinicopathological parameters of PCa patients. Transwell assay and wound healing assay was conducted to examine the invasion and migration ability of PCa cells, respectively.

RESULTS: CISD2 was up-regulated in PCa tissues and cells, and showed positive association with the poor prognosis, T stage, lymphatic invasion, prostate-specific antigen (PSA) level, and distant metastasis of PCa patients. Besides, we found that inhibition of CISD2 significantly impaired the migration and invasion ability of PCa cells.

CONCLUSIONS: The paper demonstrated that CISD2 could act as a new target for the diagnosis and treatment of PCa patients.

Free PDF Download

To cite this article

Q.-Q. Zhu, L. Tian, D.-L. Li, Z.-H. Wu, Y.-Y. He, H.-K. Zhang
Elevated CISD2 expression predicts poor diagnosis and promotes invasion and migration of prostate cancer cells

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 12
Pages: 6597-6604
DOI: 10.26355/eurrev_202006_21645